Burjeel Net Profit Surges 128.9% In The Second Quarter

Burjeel Holdings delivered strong top-line growth of 18.7 per cent to Dh1,403 million in Q2'25, driven by a 12.1 per cent increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network, the super-specialty healthcare services provider announced on Thursday.

Net profit surged 128.9 per cent to Dh148 million in Q2'25, reflecting margin expansion, enhanced operating leverage, and asset optimisation. In H1'25, net profit rose 10.6 per cent to Dh187 million.

Ebitda rose 59.4 per cent to Dh306 million in Q2'25, fuelled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes Dh72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The Ebitda margin expanded 5.6 p.p. to 21.8 per cent. In H1'25, Ebitda increased 14.2 per cent to Dh487 million, with a margin of 18.2 per cent.

Revenue in H1'25 rose 12.2 per cent to Dh2,677 million, with total patient visits reaching 3.4 million. Oncology remained a core growth driver, with revenue rising 36.7 per cent in Q2'25 and 38.1 per cent in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18 per cent), emergency medicine (+17 per cent), cardiology (+16 per cent), and gastroenterology (+13 per cent).

John Sunil, CEO of Burjeel Holdings, was optimistic about maintaining strong momentum through the second half.“We continue to target mid-teens revenue growth for the year, supported by the ramp-up of new assets and strategic expansion in both the UAE and Saudi Arabia,” he said.

A key focus is making sure that Burjeel's new centres and services are launched smoothly and begin contributing at full potential.“Major investments in specialised care, technology, and new geographies do not translate into financial returns overnight. But the strategy we have been executing is absolutely the right one, and this quarter's results are a clear example of how our growth strategy and investments in complex care are beginning to yield measurable financial results,” Sunil said.

Inpatient footfall rose 17.7 per cent in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. Outpatient footfall grew 12.0 per cent in Q2'25, accelerating from 5.2 per cent in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilisation improved to 68 per cent, up from 65 per cent in Q1'25, enabled by optimised hiring and scaling of clinical teams.

The Hospitals segment continued to drive group performance, contributing 89 per cent of total revenue in Q2'25. Revenue grew 17.3 per cent to Dh1,245 million, supported by strong growth in patient volumes and sustained demand for complex care services. Segment Ebitda rose by 40.6 per cent, led by strong performance across key hospitals.

Operating cash flow increased 8.1 per cent YoY in H1'25, driven by improved operational performance and disciplined working capital management. Maintenance capex remained in line with guidance, while growth capex totalled Dh403 million, driven by strategic M&A activities and ongoing network expansion. Free cash flow conversion improved to 54 per cent in H1'25.

In May 2025, the Group declared a full-year dividend of Dh170 million for FY2024, representing 47 per cent of net profit.

Cost control was a key contributor to the company's performance.“Even with 143 new physicians onboarded over the past year, we were able to optimise personnel costs through better workforce planning and clinical scheduling. We also brought overheads down by 7 per cent quarter-on-quarter and over 13 per cent compared to Q4, by normalising spend and embedding stronger cost discipline across the group. These efforts, alongside strong top-line growth, drove a significant improvement in margins,” Sunil said.

The Trust Fertility Center, now the largest in the UAE, broke even within six months and has served over 1,800 unique patients with outcomes well above global benchmarks.“It plays a key role in our women's health platform and aligns with the UAE's national fertility strategy. Looking ahead, we're replicating this model in Al Ain and Dubai, while continuing to invest in precision medicine, AI-enabled care, and complex specialties,” Sunil said.

MENAFN07082025000049011007ID1109900179